Eltrombopag for the treatment of refractory thrombocytopenia associated with connective tissue disease
Abstract To assess the efficacy and safety of eltrombopag in connective tissue disease (CTD)-immune thrombocytopenia (ITP), we conducted this single-center retrospective observational study, including patients with refractory CTD-ITP who were treated with eltrombopag between January 2018 and August...
Guardado en:
Autores principales: | Juan Wang, Min Dai, Qiong Fu, Sheng Chen |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/efe7af08d0f3455089981a6d8628972c |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
The role of eltrombopag in the management of hepatitis C virus-related thrombocytopenia
por: Danish FA, et al.
Publicado: (2013) -
Treatment of immune thrombocytopenic purpura: focus on eltrombopag
por: Lawrence Rice
Publicado: (2009) -
Chronic Refractory Immune Thrombocytopenia Is Associated With Variants in Immune Genes
por: Shasha Zhao MD, et al.
Publicado: (2021) -
Is the increase in eltrombopag dose cause of myocardial infarction?
por: Edip Can Özgünoğlu, et al.
Publicado: (2021) -
Eltrombopag directly inhibits BAX and prevents cell death
por: Adam Z. Spitz, et al.
Publicado: (2021)